• Home
  • Search Results
  • FDA Approved Drug Library Screening Identifies Robenidine as a Repositionable Antifungal.

FDA Approved Drug Library Screening Identifies Robenidine as a Repositionable Antifungal.

Frontiers in microbiology (2020-06-26)
Yikun Mei, Tong Jiang, Yun Zou, Yuanyuan Wang, Jia Zhou, Jinyang Li, Lin Liu, Jingcong Tan, Luqi Wei, Jingquan Li, Huanqin Dai, Yibing Peng, Lixin Zhang, Jose L Lopez-Ribot, Rebecca S Shapiro, Changbin Chen, Ning-Ning Liu, Hui Wang

Due to the increasing prevalence of pathogenic fungal infections, the emergence of antifungal resistant clinical isolates worldwide, and the limited arsenal of available antifungals, developing new antifungal strategies is imperative. In this study, we screened a library of 1068 FDA-approved drugs to identify hits that exhibit broad-spectrum antifungal activity. Robenidine, an anticoccidial agent which has been widely used to treat coccidian infections of poultry and rabbits, was identified in this screen. Physiological concentration of robenidine (8 μM) was able to significantly inhibit yeast cell growth, filamentation and biofilm formation of Candida albicans - the most extensively studied human fungal pathogen. Moreover, we observed a broad-spectrum antifungal activity of this compound against fluconazole resistant clinical isolates of C. albicans, as well as a wide range of other clinically relevant fungal pathogens. Intriguingly, robenidine-treated C. albicans cells were hypersensitive to diverse cell wall stressors, and analysis of the cell wall structure by transmission electron microscopy (TEM) showed that the cell wall was severely damaged by robenidine, implying that this compound may target the cell wall integrity signaling pathway. Indeed, upon robenidine treatment, we found a dose dependent increase in the phosphorylation of the cell wall integrity marker Mkc1, which was decreased after prolonged exposure. Finally, we provide evidence by RNA-seq and qPCR that Rlm1, the downstream transcription factor of Mkc1, may represent a potential target of robenidine. Therefore, our data suggest that robenidine, a FDA approved anti-coccidiosis drug, displays a promising and broadly effective antifungal strategy, and represents a potentially repositionable candidate for the treatment of fungal infections.

Product Number
Product Description

Calcofluor White Stain, suitable for microbiology
Calcium chloride dihydrate, for molecular biology, ≥99.0%
Alcian Blue 8GX, certified by the Biological Stain Commission

Social Media

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon


Research. Development. Production.

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Reproduction of any materials from the site is strictly forbidden without permission.